NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: BASF

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BASF Strengthens its Commitment to the Biopharma and Pharmaceutical Ingredients Industries through A New Investment in North America - BASF opens its new Good Manufacturing Practice (GMP) Solution Center, in Wyandotte, Michigan - Pharma.BASF.com
BASF Strengthens its Commitment to the Biopharma and Pharmaceutical Ingredients Industries through A New Investment in North America

 

NewswireTODAY - /newswire/ - Florham Park, NJ, United States, 2025/06/17 - BASF opens its new Good Manufacturing Practice (GMP) Solution Center, in Wyandotte, Michigan - Pharma.BASF.com. Frankfurt (BAS)

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• New Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan expands BASF’s existing network of poloxamers sites;
• Production capabilities are unique to industry and enable closer collaboration with customers on product development.

This investment underscores the ongoing commitment of BASF to providing innovative solutions in the biopharma and pharmaceutical ingredients industries, including the reliable supply of bioprocessing ingredients and excipients for biopharma applications as well as small molecules.

This new facility will play a crucial role in the expansion of BASF’s existing network of GMP sites, with innovative systems and processes that ensure products are produced consistently and controlled according to high quality standards. These practices are crucial in the pharmaceutical industry, where the quality of products is paramount for safety and efficacy.

Featuring state-of-the-art clean room packaging, and high-sensitivity analytical testing, this new facility enables close collaboration with customers on customized chemistries for product development. Additionally, improved manufacturing capabilities will allow for more tightly controlled parameters beyond compendial limits and a validated control system that allows for high reproductivity.

Marion Kuhn, vice president of business management, BASF Pharma Solutions states,“Our new GMP Solution Center exemplifies BASF’s dedication to understanding and addressing the evolving needs of our customers in both the biopharma and pharmaceutical industries. This state-of-the-art facility will play a fundamental role in enabling us to collaborate closely with our customers worldwide on product development and GMP manufacturing in ways that are unique to the industry, further strengthening our position as an innovator in the pharmaceutical sector.”

“Wyandotte's new GMP Solution Center is a key example of BASF's commitment to innovative excellence,” said Benjamin Knudsen, vice president of research North America at BASF Corporation. “This expansion not only showcases our dedication to developing customized solutions, but it also highlights our ability to adapt and innovate in response to our customers’ needs. Together, we are paving the way for new innovative solutions.”

About BASF Pharma Solutions

BASF Pharma Solutions (pharma.basf.com) produces innovative excipients and active ingredients of outstanding quality and performance. With a global team of industry experts and digital solutions, such as the Virtual Pharma Assistants, BASF supports its customers in developing efficient, cost-effective and reliable formulations. Equipped with an in-depth understanding of multiple technologies and applications, BASF has the knowledge and resources to make drug delivery and drug and biologics manufacturing safer and more sustainable.

About BASF

At BASF (basf.com), we create chemistry for a sustainable future. Our ambition: We want to be the preferred chemical company to enable our customers’ green transformation. We combine economic success with environmental protection and social responsibility. Around 112,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises, as core businesses, the segments Chemicals, Materials, Industrial Solutions, and Nutrition & Care; our standalone businesses are bundled in the segments Surface Technologies and Agricultural Solutions. BASF generated sales of €65.3 billion in 2024.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: BASF

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BASF Strengthens its Commitment to the Biopharma and Pharmaceutical Ingredients Industries through A New Investment in North America

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BASF GMP |
Contact: John Bell - BASF.com 
848-200-8874 john.bell[.]basf.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BASF securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BASF / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
NEC and Chugai Pharmaceutical Use AI to Potentially Enhance Cancer Treatment
ONO PHARMA Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL At 2025 ASCO Annual Meeting
SCHOTT Pharma Expands Ready-to-use Portfolio with Sterile 1.5 ml Cartridge
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
SCHOTT Pharma Opens Production Facility in Serbia to Strengthen Competitiveness in Europe
NEC Has Developed Technologies that Enable A Secure Workflow for Personalized Cancer Vaccines and Has Proven their Capabilities
BASF Aroma Ingredients Innovates with Two New Isobionics® Biotech Flavor Ingredients
Federal Government Invests .9 Million in STEMCELL Technologies Canada, Inc.
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)